Novavax reports positive phase 1 data on its Covid-19 vaccine candidate

Gaithersburg’s Novavax Inc. (NASDAQ: NVAX) reported Tuesday positive phase 1 clinical trial data on its Covid-19 vaccine candidate, a necessary step to advance a product that, officials hope will eventually protect people from the coronavirus. The study found the candidate, called NVX-CoV2373, to both be generally well-tolerated and elicit “robust antibody responses,” the company said Tuesday, adding that it showed the potential to reduce the disease’s transmission. Specifically, the candidate…